AtaiBeckley Inc. 4

Director Scott Braunstein’s AtaiBeckley stock options covering a total of 573,881 shares were cancelled in the Eli Lilly merger and converted into cash and contingent value rights.

On September 11, 2026, in connection with the closing of Eli Lilly and Company’s acquisition of AtaiBeckley Inc., all of Scott Braunstein’s outstanding stock options in AtaiBeckley were automatically cancelled and converted into a right to receive cash plus contingent value rights (CVRs). Specifically, four tranches of options with exercise prices of $1.34, $2.25, $5.28, and $4.50 per share covering 206,000, 103,000, 56,818, and 208,063 shares of common stock, respectively, were terminated at the merger’s effective time. Each option share is now entitled to a cash payment equal to $6.75 minus the relevant exercise price, plus one CVR per share, which may pay up to an additional $2.50 per share upon achievement of specified clinical and regulatory milestones. After these transactions tied to the merger, Braunstein no longer holds these options, and his post‑transaction holdings in the reported securities and their value are effectively reduced to zero.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036380

Alert Tier

5